Live Chat on The Biotech Forum has been dominated by discussion of covered call opportunities in recent quarters. To see what I and the other season biotech investors are targeting as trading ideas in real-time, just initiate your free trial into The Biotech Forum by clicking HERE .Today, I am putting DexCom, Inc. (NASDAQ: DXCM ) in the spotlight. The stock of this medical device concern got a bit of a temporary boost of 10% in late June when the Department of Health and Human Services announced itBret lead ...

Key Takeaways JNJ beat Q2 estimates and raised full-year guidance on strong pharma performance. Innovative Medicine sales rose despite Stelara LOE, aided by key drugs and new launches. MedTech improvement was led by cardiovascular and surgical products, which offset China-related headwinds.Johnson & Johnson (JNJ) delivered strong second-quarter 2025 results, with both the top and bottom lines exceeding expectations.Despite the loss of exclusivity (“LOE”) of its multi-billion-dollar product, Stelara, J&J’s ...

Tandem Diabetes Care, Inc. (TNDM) has been on a downward spiral lately with significant selling pressure. After declining 27% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a ...

J P M O R G A N Asia Pacific Equity Research 18 July 2025 MicroPort (0853) Pre-announced 1H25 sales and adj net profit slightly below expectations, but 2H25 offers potential for recovery. Maintain OW MicroPort (853 HK, OW) pre-announced its 1H2025 results last night, indicating a sales decline of less than 4% (excluding forex effects) and an adjusted net loss limited to US$110mn. The announcement mentioned several challenges in 1H25, such as intensifying domestic competition, policy-induced price adjustment ...

Wall Street analysts forecast that Edwards Lifesciences (EW) will report quarterly earnings of $0.62 per share in its upcoming release, pointing to a year-over-year decline of 11.4%. It is anticipated that revenues will amount to $1.49 billion, exhibiting a decrease of 8.9% compared to the year-ago quarter.The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this ...

LOS ANGELES, July 21, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or "the Company") (NASDAQ: RXST) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. RxSight reported its Q2 2025 financial results on July 9, 2025. The Company revealed ...

With over 80 issued patents and 40 pending patent applications, Autonomix is building a comprehensive IP portfolio in nerve-sensing and modulation, strengthening its strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, July 21, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted ...

GALWAY, Ireland, July 21, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in medical technology, today announced CE (Conformité Européenne) Mark in Europe to expand indications of the MiniMed™ 780G system for use by individuals aged 2 years and older, during pregnancy, as well as type 2 insulin-requiring diabetes. To gain CE Mark for this expansion of indications, published clinical data in 2–6-year-olds, pregnant women, and people living with type 2 diabetes was reviewed. This expanded indi ...

EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced the appointment of Robert McMahon as the company's new Chief Financial Officer (CFO), effective August 4, 2025. Mr. McMahon will succeed Bernard Birkett, CFO, who announced his intention to retire earlier this year. Mr. Birkett will assume the role of Senior Advisor to the CEO through the end of the year to ensure a seamless tra ...

Medical device specialist DexCom (DXCM -0.33%) has encountered significant headwinds in the past year. The company's financial results haven't been quite up to the market's standards, and broader market volatility caused by President Donald Trump's trade policies isn't helping either. The stock is down 26% over the trailing-12-month period.Yet even with all these challenges, DexCom could be a terrific performer in the next five years. Here's why.There's plenty of white space aheadDexCom markets continuous g ...